TAVR is Here! - TriStar Health

More documents

Recommendations

Info

The Partner Trial – Cohort B September 22, 2010 on NEJM.org
Objectives • To evaluate the clinical outcomes of the Edwards SAPIEN transcatheter heart valve (THV) compared to standard therapy at 2 years in “inoperable” patients with severe symptomatic native aortic valve stenos<strong>is</strong> • To assess valve hemodynamic performance using echocardiography • To perform analyses to better define the impact of comorbidities on outcomes 7
Page 1 and 2: Current Status of Percutaneous Aort
Page 3 and 4: Who gets a TAVR • Severe , sympto
Page 8 and 9: Aortic Stenosis
Page 10 and 11: Undertreatment Is Profound
Page 12 and 13: TA, transapical; TF, transfemoral.
Page 14 and 15: Strict Site Selection St. Paul's Ho
Page 16 and 17: Stringent Patient Screening Screeni
Page 18 and 19: An Elderly and Highly Symptomatic P
Page 20 and 21: Patients Had Multiple Severe Comorb
Page 22 and 23: Standard Therapy Is Failing These P
Page 24 and 25: 30% Absolute Reduction in Cardiovas
Page 26 and 27: Error bars = ± 1 Std Dev Reduced M
Page 28 and 29: Significant Improvement in 6-Minute
Page 30 and 31: Higher Incidence of Stroke 30
Page 32 and 33: Higher Incidence of Major Vascular
Page 34 and 35: New Pacemaker Implantation
Page 36 and 37: Conclusions At 2 years, in patients
Page 38: Clinical Implications • Two-year
Page 41 and 42: What’s next • High Risk surgica
Page 43: One Call… 855-900-VALVE

TAVR is Here! - TriStar Health

Create successful ePaper yourself

Delete template?

Save as template?